Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Durvalumab + Gemcitabine + Oxaliplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 109||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 14||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 7||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05771480||Phase III||Durvalumab + Gemcitabine + Oxaliplatin Cisplatin + Durvalumab + Gemcitabine + Tegafur-gimeracil-oteracil Potassium Durvalumab + Gemcitabine + Tegafur-gimeracil-oteracil Potassium Cisplatin + Durvalumab + Gemcitabine Durvalumab + Gemcitabine Carboplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + Nab-paclitaxel||Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)||Recruiting||USA | ITA | FRA | ESP | DEU||3|